Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Caen
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient (\> 18 years) with relapsing-remitting multiple sclerosis. Initiation of treatment of 1st line: interferon β, peginterferon β, glatiramer acetate, teriflunomide, dimethyl-fumarate.
You may not be if
Patient with progressively progressive secondary or multiple sclerosis. Patient suffering from multiple sclerosis not treated with a first line treatment.
Clareo Health | E-reporting of Adverse Drug Reactions by Patients in Relapsing-remitting Multiple Sclerosis
